An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes (SHIELD-ET)
2026년 8월 26일 업데이트: Bayer
Study of Real-world Use of Hormonal Levonorgestrel Intra-uterine System for Endometrial Defense With Estrogen Therapy
This is an observational study in which researchers will use claims data already collected from women in the United States who received their usual care. The study will look at women aged 40 years and older who have a uterus and started estrogen therapy.
Estrogen therapy is often used to treat menopause symptoms, such as hot flashes and night sweats, or to help prevent bone loss. Women who take estrogen and still have a uterus usually also need a progestogen to help protect the lining of the uterus. Without this protection, the lining may become too thick. This can lead to endometrial hyperplasia and may increase the risk of endometrial cancer.
This study will look at how Mirena and other progestogen treatments are used in routine medical care to protect the lining of the uterus during estrogen therapy. Mirena is a small device placed in the uterus that releases the hormone levonorgestrel (a synthetic progestogen, similar to progesterone). In the United States, Mirena is approved for birth control and for treatment of heavy menstrual bleeding. Clinicians may also use it for endometrial protection during estrogen therapy. Bayer's Mirena levonorgestrel-containing intrauterine system (LNG-IUS) 52 mg is approved for endometrial protection during hormone therapy in over 100 countries outside of the US.
The main purpose of this study is gain insight into how different progestogen treatments are used in the context of estrogen therapy in women with a uterus, and the health outcomes linked with them. Researchers will describe how often women use estrogen alone, estrogen with Mirena, or estrogen with other progestogen treatments in the past 10 years. Researchers will also look at how often endometrial hyperplasia, endometrial cancer, abnormal or heavy bleeding, and hysterectomy occur in these groups over time.
The data will come from two U.S. health insurance claims databases: Optum Clinformatics Data Mart and MarketScan Commercial Claims and Encounters Database. The study period covers 2014 through 2025, depending on the database. Optum: January 2015-December 2025 and MarketScan: October 2014-September 2025, with patient identification periods of Optum: January 2016-December 2024 and MarketScan: October 2015-September 2024. Researchers will follow each participant's available data for at least 12 months before and at least 12 months after starting estrogen therapy, with follow-up of up to 10 years.
No study treatment will be given as part of this study. Researchers will only review anonymous health insurance claims data that were already collected during routine care.
연구 개요
상태
아직 모집하지 않음
연구 유형
관찰
등록 (추정된)
456000
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 연락처
- 이름: Bayer Clinical Trials Contact
- 전화번호: 18888422937
- 이메일: clinical-trials-contact@bayer.com
연구 장소
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48108
- Mirative MarketScan Commercial Claims and Encounters Database
-
-
Minnesota
-
Eden Prairie, Minnesota, 미국, 55344
- Optum Clinformatics™ Data Mart (CDM)
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
샘플링 방법
비확률 샘플
연구 인구
The study population for the SHIELD-ET study are patients 40+ years of age with a uterus receiving estrogen therapy.
Special populations or subpopulations among menopausal women (e.g.
chemotherapy- or drug-induced menopause), as well as women without a uterus will be excluded.
설명
Inclusion Criteria:
- At least one claim of estrogen therapy (ET) during the patient identification period (Index date: the first claim for ET)
- Age ≥ 40 years at the index date
- Patients with minimum continuous enrollment 12 months prior and 12 months at minimum after index date
Exclusion Criteria:
- Women without a uterus (claims of hysterectomy) in the 12-month baseline period
- Use of any hormonal contraception in the 12-month baseline period
- Claims indicative of atypical endometrial hyperplasia or endometrial cancer or heavy menstrual bleeding (HMB)/abnormal uterine bleeding (AUB)/postmenopausal bleeding (PMB), or any treatment for late state or metastatic endometrial cancer, in the baseline period.
- Claims in the baseline period for any of the treatments of interest
- Claims of chemotherapy/endocrine therapy in the baseline period
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Estrogen therapy (ET) unopposed
Women receiving estrogen therapy (ET) alone without evidence of concomitant progestogen use during the exposure assessment period.
|
Estrogen therapy prescribed during routine clinical practice and identified through prescription claims data.
Exposure to estrogen therapy is determined using study-specific claims-based definitions.
|
|
ET + Mirena LNG-IUS
Women receiving estrogen therapy (ET) with recurring prescription fills and evidence of Mirena levonorgestrel-releasing intrauterine system (LNG-IUS) use, identified through a Mirena insertion procedure code and/or device code during the exposure assessment period.
|
A levonorgestrel-releasing intrauterine system used for endometrial protection in women receiving estrogen therapy.
Exposure is identified through Mirena insertion procedure codes and/or device codes in claims data.
Contraception use of this product is not exposure of interest and baseline hormonal contraception is an exclusion criterion.
다른 이름들:
|
|
ET + other progestogen
Women receiving estrogen therapy (ET) with recurring prescription fills and evidence of concomitant progestogen use other than Mirena LNG-IUS during the exposure assessment period.
Other progestogen therapies include progesterone, synthetic progestins, Liletta LNG-IUS 52 mg, and combination estrogen-progestogen products.
|
rogestogen therapy used for endometrial protection in women receiving estrogen therapy, including progesterone, synthetic progestins, Liletta LNG-IUS 52 mg, and combination estrogen-progestogen products.
Exposure is identified through claims data.
Contraceptive use of these products is not exposure of interest, and baseline hormonal contraception is an exclusion criterion.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of patients receiving estrogen therapy
기간: Retrospective analysis from January 2025 to December 2025
|
Proportion of eligible female patients aged 40 years and older with a uterus who received at least one claim for estrogen therapy during the study period.
The numerator is the number of patients with at least one estrogen therapy claim during the study period, and the denominator is the number of eligible female patients contributing at least one observable person-day during the study period.
|
Retrospective analysis from January 2025 to December 2025
|
|
Number of patients by treatment subgroup within 30 and 90 days of estrogen therapy initiation
기간: Within 30 days and 90 days after estrogen therapy initiation during the study period (January 2025 to December 2025)
|
Number of patients in each treatment subgroup (ET unopposed, ET + Mirena LNG-IUS, and ET + other progestogen) within 30 and 90 days after initiation of estrogen therapy.
|
Within 30 days and 90 days after estrogen therapy initiation during the study period (January 2025 to December 2025)
|
|
Proportion of patients by treatment subgroup within 30 and 90 days of estrogen therapy initiation
기간: Within 30 days and 90 days after estrogen therapy initiation during the study period (January 2025 to December 2025)
|
Proportion of patients in each treatment subgroup (ET unopposed, ET + Mirena LNG-IUS, and ET + other progestogen) within 30 and 90 days after initiation of estrogen therapy.
|
Within 30 days and 90 days after estrogen therapy initiation during the study period (January 2025 to December 2025)
|
|
Average length of estrogen therapy use
기간: Retrospective analysis from January 2025 to December 2025
|
The average length of estrogen therapy (ET) use will be expressed as the mean duration (in days) among all eligible patients.
The length of ET use will be measured as the time from the first ET prescription date to the last ET prescription date, with a maximum allowable gap of 30 days between consecutive prescriptions to be considered continuous therapy.
|
Retrospective analysis from January 2025 to December 2025
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall (10-year) incidence of atypical, non-atypical and unspecified endometrial hyperplasia, endometrial cancer, abnormal/unscheduled/heavy menstrual bleeding and hysterectomy
기간: Retrospective analysis from January 2016 to December 2025
|
Overall incidence of atypical, non-atypical, and unspecified endometrial hyperplasia, endometrial cancer, abnormal/unscheduled/heavy menstrual bleeding, and hysterectomy among patients in each treatment subgroup (ET unopposed, ET + Mirena LNG-IUS, and ET + other progestogen).
Overall incidence will be evaluated over the 10-year study period.
For each outcome, incident cases are defined as patients with at least one new claim for the condition of interest during follow-up.
Only the first occurrence of each outcome after the index date will be counted as an incident event.
Outcomes are assessed after completion of the 30- and 90-day exposure assessment periods, and only first incident events during follow-up are counted.
|
Retrospective analysis from January 2016 to December 2025
|
|
Annual incidence of atypical, non-atypical and unspecified endometrial hyperplasia, endometrial cancer, abnormal/unscheduled/heavy menstrual bleeding and hysterectomy
기간: Annually from January 2016 through December 2025
|
Annual incidence of atypical, non-atypical, and unspecified endometrial hyperplasia, endometrial cancer, abnormal/unscheduled/heavy menstrual bleeding, and hysterectomy among patients in each treatment subgroup (ET unopposed, ET + Mirena LNG-IUS, and ET + other progestogen).
For each outcome, incident cases are defined as patients with at least one new claim for the condition of interest during follow-up.
Patients will be counted only in the calendar year of their first occurrence for each outcome.
|
Annually from January 2016 through December 2025
|
|
Participant demographic characteristics: age
기간: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
|
|
Participant demographic characteristics: race
기간: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
|
|
Participant demographic characteristics: ethnicity
기간: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
|
|
Participant demographic characteristics: region
기간: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
|
|
Participant demographic characteristics: health plan type
기간: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
|
|
Gynecologic history: endometrial polyps, fibroids, adenomyosis, endometriosis
기간: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
|
|
Clinical characteristics: relevant comorbidities
기간: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
|
|
Clinical characteristics: Charlson Comorbidity Index (CCI)
기간: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
The CCI is a method of estimating the one-year mortality for a patient with certain comorbid conditions.
Each comorbid condition is given a score of 1, 2, 3 or 6 based on the degree of mortality attributed to the condition.
The scores are summed to yield a total index score which can be used to predict long-term survival.
Higher scores indicate a greater comorbidity burden and a higher predicted risk of mortality.
|
At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
|
Proportion of patients with a diagnosis of menopause
기간: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
At baseline (within 12 months before the first estrogen therapy prescription claim [index date])
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
2026년 8월 31일
기본 완료 (추정된)
2026년 10월 30일
연구 완료 (추정된)
2026년 12월 31일
연구 등록 날짜
최초 제출
2026년 8월 26일
QC 기준을 충족하는 최초 제출
2026년 8월 26일
처음 게시됨 (실제)
2026년 8월 31일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 8월 31일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 8월 26일
마지막으로 확인됨
2026년 8월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 23357
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
아니요
IPD 계획 설명
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing".
This pertains to scope, timepoint and process of data access.
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research.
This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research.
Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .